OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro.
OKY-1581 is an effective inhibitor of thromboxane synthesis in vivo and in vitro. The generation of thromboxane B2 (TxB2), prostaglandin E (PGE) and prostaglandin F (PGF) was measured following clotting and during platelet aggregation induced by collagen. The presence of OKY 1581 either in vivo or in vitro caused a reduction in TxB2 generation during clotting and platelet aggregation with a concomitant increase in PGE and PGF. The effect could be observed two hours after oral or subcutaneous administration of 5 to 100 mg per rabbit and lasted for 24 to 48 hours. The reduction in TxB2 was not accompanied by an inhibition of clotting or platelet aggregation. OKY-1581 appears to be a suitable agent for studying the role of TxB2 in atherosclerosis.
D000179:Acrylates / Q000494:pharmacology*; D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D008689:Methacrylates / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D011458:Prostaglandins E / Q000097:blood; D011460:Prostaglandins F / Q000097:blood; D011817:Rabbits; D013929:Thromboxane B2 / Q000097:blood*; D013931:Thromboxanes / Q000097:blood*
D000179:Acrylates; D008689:Methacrylates; D011458:Prostaglandins E; D011460:Prostaglandins F; D013931:Thromboxanes; D013929:Thromboxane B2; C031517:2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid